Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 25:13:1648379.
doi: 10.3389/fcell.2025.1648379. eCollection 2025.

Advances in mechanisms and challenges in clinical translation of synergistic nanomaterial-based therapies for melanoma

Yibo Zhang #  1 , Xilin Liu #  2 , Guangzhi Wu  1
Affiliations
Review

Advances in mechanisms and challenges in clinical translation of synergistic nanomaterial-based therapies for melanoma

Yibo Zhang et al. Front Cell Dev Biol. .

Abstract

Melanoma is a highly malignant form of skin cancer, with its incidence and mortality rates continuously rising on a global scale. Although traditional treatments such as surgery, chemotherapy, radiotherapy, as well as targeted and immunotherapy, have made certain progress, the efficacy of these therapeutic modalities remains limited due to the high metastatic potential, heterogeneity, and drug resistance of melanoma. In recent years, nanomaterials, with their unique physicochemical properties, have emerged as a significant research focus in tumor therapy. Nanomaterials can enhance the targeted delivery of drugs, increase drug accumulation in tumors, and reduce side effects, and they have shown great potential in the synergistic treatment of melanoma. This review summarizes the mechanistic breakthroughs of nanomaterials in the synergistic treatment of melanoma, including the combined application of nanocarriers in photothermal therapy, photodynamic therapy, and immunotherapy. It also explores how precise drug delivery can improve therapeutic efficacy and overcome tumor immune evasion and drug resistance. Furthermore, the challenges faced in the clinical translation of nanomaterial-based synergistic treatment are discussed, such as biosafety, delivery efficiency, and the need for personalized treatment. Despite these challenges, the continuous development of nanotechnology offers new hope for the comprehensive treatment of melanoma and lays the foundation for the realization of precision medicine in the future.

Keywords: clinical translation; melanoma; nanomaterials; precision medicine; synergistic therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
The biological characteristics of tumors bring about significant challenges.
FIGURE 2
FIGURE 2
The unique advantages of nanodrug delivery.
FIGURE 3
FIGURE 3
The synergy of targeted delivery and immune regulation.
FIGURE 4
FIGURE 4
The synergy of PDT/PTT and immunity.
FIGURE 5
FIGURE 5
The synergy of dynamic monitoring and precision intervention.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Ahijado-Guzmán R., Sánchez-Arribas N., Martínez-Negro M., González-Rubio G., Santiago-Varela M., Pardo M., et al. (2020). Intercellular trafficking of gold nanostars in uveal melanoma cells for plasmonic photothermal therapy. Nanomaterials 10, 590. 10.3390/nano10030590 - DOI - PMC - PubMed
    1. Alharbi B., Qanash H., Binsaleh N. K., Alharthi S., Elasbali A. M., Gharekhan C. H., et al. (2023). Proof of concept nanotechnological approach to in vitro targeting of malignant melanoma for enhanced immune checkpoint inhibition. Sci. Rep. 13, 7462. 10.1038/s41598-023-34638-2 - DOI - PMC - PubMed
    1. Allami P., Heidari A., Rezaei N. (2023). The role of cell membrane-coated nanoparticles as a novel treatment approach in glioblastoma. Front. Mol. Biosci. 9, 1083645. 10.3389/fmolb.2022.1083645 - DOI - PMC - PubMed
    1. Almomen A., El-Toni A. M., Badran M., Alhowyan A., Abul Kalam M., Alshamsan A., et al. (2020). The design of anionic surfactant-based amino-functionalized mesoporous silica nanoparticles and their application in transdermal drug delivery. Pharmaceutics 12, 1035. 10.3390/pharmaceutics12111035 - DOI - PMC - PubMed
    1. Amaral T., Seeber O., Mersi E., Sanchez S., Thomas I., Meiwes A., et al. (2020). Primary resistance to PD-1-Based immunotherapy—A study in 319 patients with stage IV melanoma. Cancers 12, 1027. 10.3390/cancers12041027 - DOI - PMC - PubMed

LinkOut - more resources